Clinical Trial Update: A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial assessed the safety and tolerability of combining enzalutamide with abiraterone acetate in bone-metastatic castration-resistant prostate cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-02-05